Seborrheic dermatitis, increased sebum excretion, and parkinson's disease: A survey of (im)possible links

Medical Hypotheses

Volumn 60, Issue 6, 2003, Pages 907-911

  Mastrolonardo, Mario ^a,c   Diaferio, A ^a   Logroscino, G ^b  

^a Azienda Ospedaliero Universitaria   (Italy)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; BIPOLAR DISORDER; CHROMOSOME ABERRATION; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DOWN SYNDROME; HEART DISEASE; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; REVIEW; SCHIZOPHRENIA; SEBACEOUS GLAND; SEBORRHEIC DERMATITIS; SEBUM SECRETION; SPINAL CORD INJURY; TARDIVE DYSKINESIA; TRIGEMINAL NERVE DISEASE;

EID: 0037410573     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00094-X     Document Type: Review

References (45)

1. Kligman A. M. Perspectives and problems in cutaneous gerontology. J Invest Dermatol 1979; 73: 39-46.
2. Skin conditions and related need for medical care among persons 1-74 years, United States, 1971-74. Vital Health Star [11], no 212, US Dept of Health, Education and Welfare, November 1978.
3. Burton J. L. Seborrheic dermatitis. In: A. Rook, D. S. Wilkinson, F. J. G. Ebling (eds), Textbook of Dermatology, vol. 14, 5th edition. Oxford: Blackwell Scientific Publications, 1992: 1561-1622.
4. Plewig S., Jansen T. Seborrheic dermatitis. In: T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Freedberg, K. F. Austen (eds). Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill, 1999: 1482-1489.
5. Gupta A. K., Kohli Y., Summerbell R. C. et al. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001; 39: 243-251.
6. Watanabe S., Kano R, Sato H. et al. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol 2001; 116: 769-773.
7. Faergemann J., Bergbrant I. M., Dohse M. et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144: 549-556.
8. Cassano N., Loconsole F., Mastrolonardo M., Vena G. A. Terbinafina orale nella dermatite seborroica: meccanismo d'azione ed esperienze cliniche preliminari. In: C. A. Bartoletti (ed). Medicina estetica: metodologie diagnostiche, preventive e correttive. Roma: Editrice Salus Internazionale, 1998: 757-765.
9. Faergemann J. Treatment of seborrhoeic dermatitis with oral terbinafine? Lancet 2001; 358: 170.
10. Moehrle M., Dennenmoser B., Schlagenhauff B. et al. High prevalence of seborrhoeic dermatitis on the face and scalp in mountain guides. Dermatology 2000; 201: 146-147.
11. Siderowf A. Parkinson's disease: clinical features, epidemiology and genetics. Neurol Clin 2001; 19: 565-578.
12. Tager A., Berlin C. Seborrheic dermatitis in acute cardiac disease. Br J Dermatol 1964; 76: 367-369.
13. Barba A., Piubello W., Vantini I. et al. Skin lesions in chronic alcoholic pancreatitis. Dermatologica 1982; 164: 322-326.
14. Guillaume J.-C., Karneff M. C., Revuz J. Dérmite séborrhéique et cancers des voies aéro-digestives supérieures. Ann Dermatol Venereol 1991; 118: 607-609.
15. Cliff D. C., Dodd H. J., Kirby J. D. et al. Seborrheic dermatitis and malignancy. Acta Derm Venereol (Stockh) 1988; 68: 48-52.
16. Ercis M., Balci S., Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetic unit. Clin Genet 1996; 50: 317-320.
17. Binder R. L., Jonelis F. J. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 1983; 119: 473-475.
18. Binder R. L., Jonelis F. J. Seborrheic dermatitis: a newly reported side effect of neuroleptics. J Clin Psychiatry 1984; 45: 125-126.
19. Maietta G., Fornaro P., Rongioletti F., Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol (Stockh) 1990; 70: 432-434.
20. Pochi P. E., Strauss J. S., Mescon H. Sebum production and fractional 17-ketosteroid excretion in parkinsonism. J Invest Dermatol 1962; 38: 45-50.
21. Sandyk R. Melanocyte-stimulating hormone in tardive dyskinesia. Biol Psychiatry 1989; 26: 213-214.
22. Bettley F. R., Marten R. H. Unilateral seborrheic dermatitis following a nerve lesion. Arch Dermatol 1956; 73: 110-115.
23. Wilson C. L., Walshe M. Incidence of seborrheic dermatitis in spinal injury patients. Br J Dermatol 1988; 119(suppl): 48.
24. Riley D., Lang A. Movement disorders. In: W. Bradley, R. Daroff, G. Fenichel, D. Marsded (eds). Principles of Neurology. Newton: Butterworth-Heineman, 1996: 1733-1772.
25. Cohn T. Encephalitis ohne Lethargie während der Grippeepidemie. Zbl Neurochir 1920; 39: 260-264.
26. Stiefler G Die Seborrhoea faciei als ein Symptom der Encephalitis lethargica. Z Neurol Psychiat 1921; 73: 455-463.
27. Krestin D. The soborrhoeic facies as a manifestation of postencephalitic parkinsonism and allied disorders. Quart J Med 1927; 21: 177-186.
28. Weidman F. B. Seborrheic dermatitis in a series of cases of postepidemic encephalitis. A M A Arch Derm 1930; 21: 690-691.
29. Burton J. L., Shuster S. Effect of L-dopa on seborrhoea of parkinsonism. Lancet 1970; 2(7662): 19-20.
30. Cotterill J. A., Cunliffe W. J., Williamson B. Sebum-excretion rate and skin-surface lipid composition in Parkinson's disease before and during therapy with L-dopa. Lancet 1971; i: 1271-1272.
31. Burton J. L., Cartlidge M., Cardidge N. E. F., Shuster S. Sebum excretion in Parkinsonism. Br J Dermatol 1973; 88: 263-266.
32. Burton J. L., Cartlidge M., Shuster S. Effect of L-dopa on the seborrhea of Parkinsonism. Br J Dermatol 1973; 88: 475-479.
33. Kohn S. R., Pochi P. E., Strauss J. S. et al. Sebaceous gland secretion in Parkinson's disease during L-dopa treatment. J Invest Dermatol 1973; 60: 134-136.
34. Shuster S., Burton J. L., Thody A. J. et al. Melanocyte-stimulating hormone and parkinsonism. Lancet 1973; 1(7801): 463-464.
35. Martignoni E., Godi L., Pacchetti C. et al. Is seborrhea a sign of autonomic impairment in Parkinson's disease. J Neural Transm 1997; 104: 1295-1304.
36. Fisher M., Gemende I., Marsch W. C., Fisher P. A. Skin function and skin disorders in Parkinson's disease. J Neural Transm 2001; 108: 205-213.
37. Parish L. C. L-dopa for seborrheic dermatitis. N Engl J Med 1970; 283: 879.
38. Harville D. D., Appenzeller O. A new approach to the reduction of sebum secretion. Arch Dermatol 1971; 103: 492-493.
39. Cowley N. C., Farr P. M., Shuster S. The permissive effect of sebum in seborrheic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol 1990; 122: 71-76.
40. O'Neill C. J., Richardson M. D., Charlett A. et al. Could seborrheic dermatitis be implicated in the pathogenesis of parkinsonism. Acta Neurol Scand 1994; 89: 252-257.
41. Burton J. L., Pye R. J. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J 1983; 286: 1169-1170.
42. Penrose L. S., Penrose R. Impossible objects: a special type of visual illusion. Br J Phychology 1958; 49: 31-33.
43. Tindall J. P. Skin changes and lesions in our senior citizens: incidences. Cutis 1976; 18: 359-362.
44. Beauregard S., Gilchrest B. A. A survey of skin problems and skin care regimens in the elderly. Arch Dermatol 1987; 123: 1638-1643.
45. Naldi L. Epidemiologia. In: T. M. Lotti (ed). La dermatite seborroica Nuovi concetti e nuove terapie. Milano: UTET Periodici, 2001: 9-12.